ARTICLE | Company News
Vical, Merck deal
November 8, 1999 8:00 AM UTC
VICL received a $2 million payment from partner Merck that extends Merck's exclusive worldwide rights to use VICL's naked DNA gene delivery technology to develop therapeutic vaccines against HIV and h...